Clinical Evaluation of the Serum Free Light Chain Analysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01423344
Recruitment Status : Unknown
Verified August 2011 by Charlotte Toftmann Hansen, University of Southern Denmark.
Recruitment status was:  Recruiting
First Posted : August 25, 2011
Last Update Posted : August 25, 2011
Information provided by (Responsible Party):
Charlotte Toftmann Hansen, University of Southern Denmark

August 24, 2011
August 25, 2011
August 25, 2011
February 2011
February 2012   (Final data collection date for primary outcome measure)
Time to 50% reduction in the concentration of the abnormal serum free light chain compared to 50% reduction in M-protein [ Time Frame: 1, 2, 3, 4 and 5 days, 2, 3 and 6 weeks after therapy, ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
Clinical Evaluation of the Serum Free Light Chain Analysis
Assessment of the Value of the Free Kappa and Free Lambda Light Chain Assay in Clinical Evaluation of Response to Treatment

Background: in patients with multiple myeloma there is a raised level of a protein, named M-protein. This M-protein is normally used to monitor disease status and evaluate response to treatment, as a decrease in M-protein is taken as evidence of therapeutic efficacy. However, the M-protein has a long half life in serum, approximately three weeks, which tend to be a practical problem, since the investigators can first determine hereafter if the treatment is effective.

A new assay has the possibility only to measure part of this protein, namely "the light chains", which also is measured in a blood sample. The half life of these light chains is much shorter, namely 2-6 hours. In theory, this means a more rapid measure of the effect of a given treatment, thereby being able to determine earlier if the treatment should continue or changed to another strategy.

Purpose: the purpose of this study is to evaluate the clinical value of the use of the serum free light chain (sFLC) assay in comparison to the M-protein in monitoring patients under treatment for multiple myeloma.

Method: the investigators measure sFLC in patients receiving there 1st treatment, either at the time of diagnosis or in the relapse setting. sFLC is measured on a regular basis, and the results are compared to the M-protein.

Not Provided
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
serum and urine
Non-Probability Sample
Newly diagnosed patients with multiple myeloma, with medical needs and known patients with multiple myeloma at there 1st relapse and medical needs
Multiple Myeloma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
February 2012
February 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • diagnosis of multiple myeloma
  • abnormal serum free light chains
  • medical needs of anti-myeloma therapy
  • receiving standard anti-myeloma therapy

Exclusion Criteria:

  • dialysis
  • normal serum free light chains
  • dementia
Sexes Eligible for Study: All
Child, Adult, Senior
Contact information is only displayed when the study is recruiting subjects
Danish Ethics comittee ( Other Identifier: S-VF-20050035 )
Not Provided
Not Provided
Charlotte Toftmann Hansen, University of Southern Denmark
Charlotte Toftmann Hansen
Not Provided
Principal Investigator: Charlotte T Hansen, Fellow Department of Haematology, research unit
University of Southern Denmark
August 2011